Johns Hopkins Pain-Neuron Model Becomes a Drug as SereNeuro Closes Oversubscribed Pre-Seed

SereNeuro Therapeutics has closed an oversubscribed pre-seed financing to advance its non-opioid pain pipeline, but the Baltimore company did not disclose the amount, the valuation, or the names of the participating investors.

The company said two Maryland venture firms and a physician investor backed the round. That leaves both the size of the financing and the composition of the investor group outside the public record.

SereNeuro's lead candidate, SN101, started life as a research model rather than a therapy. Johns Hopkins scientists created human pain-sensing neurons from induced pluripotent stem cells to study peripheral pain, placed those cells into a joint model, and observed an unexpected therapeutic effect. Scientific co-founder Xinzhong Dong has said the model was never intended to become a drug; the result in the joint-pain model changed the direction of the work.

SN101 is now described as an off-the-shelf therapy made from purified human nociceptors. SereNeuro says the cells carry the channel identity of native dorsal root ganglion neurons, including Nav1.7, Nav1.8 and Nav1.9. Delivered by injection into an affected joint, the candidate is designed to sequester inflammatory pain factors while preserving joint structure. The company also says the cells release regenerative factors that may help preserve cartilage, though those claims remain preclinical.

The biology inverts the usual approach. Pain medicine typically tries to block or quiet nociceptors, the sensory neurons that detect damaging stimuli. SereNeuro is developing a treatment that adds mature nociceptors to an arthritic joint and asks those cells to absorb inflammatory pain factors without relaying the signals to the brain.

SereNeuro presented preclinical SN101 findings at an International Society for Stem Cell Research symposium in December 2025, reporting pain relief and reduced cartilage degeneration in preclinical models. Independent Technical.ly reporting says the company has tested the therapy in primates and collected data from joint-fluid samples from people with osteoarthritis. Those signals support continued development, but they are not evidence of safety or efficacy in patients.

The new capital moves SN101 deeper into the manufacturing and preclinical work required for an Investigational New Drug application. CEO and co-founder Daniel Saragnese said the round and the company's non-dilutive funding will support those studies. Technical.ly reported that SereNeuro was preparing for a November 2026 meeting with the FDA and had already used some financing to add staff.

The leadership team includes Laura Richman as chief scientific officer, Oliver Kraemer as chief technology officer, and Tea Soon Park as senior principal scientist for cell therapy. For an iPSC-derived therapy, manufacturing is part of the medicine: cell identity, purity, maturity, consistency and delivery all shape the risk profile.